1. Introduction {#sec1}
===============

Mesenchymal stem cells (MSCs) are multipotent fibroblast-like cells that reside in many adult tissues such as bone marrow adipose tissue \[[@B1], [@B2]\], liver \[[@B3]\], muscle connective tissue \[[@B4]\], amniotic fluid \[[@B5]\], placenta \[[@B6], [@B7]\], umbilical cord blood \[[@B1]\], and dental pulp \[[@B8], [@B9]\]. Although their differentiation potentials are primarily osteogenesis, chondrogenesis, and adipogenesis, MSCs have been reported to have the potential to differentiate into an amazing array of cell types that include nearly every major cell types in the adult body \[[@B10], [@B11]\]. MSCs are currently the most evaluated experimental stem cells with more than 100 clinical trials in 2010 to test their efficacy in treating a myriad of diseases such as cardiovascular diseases (e.g., acute myocardial infarction, endstage ischemic heart disease, or prevention of vascular restenosis), osteogenesis imperfecta (OI) or brittle bone disease, amyotrophic lateral sclerosis (ALS), lysosomal storage diseases (e.g., Hurler syndrome), steroid refractory graft versus host disease (GVHD), periodontitis and bone fractures \[[@B12]\].

The use of MSCs as therapeutics was initially predicated on the hypothesis that transplanted MSCs home and engraft in injured tissues, and then differentiate into cells to replace damaged cells. However, it has been estimated that \<1% of transplanted cells actually reached the target tissue with most of the cells being trapped in the liver, spleen, and lung \[[@B13]\], and reported evidence for differentiation of transplanted MSCs at the site of injury often cannot eliminate the possibility of cell fusion \[[@B14]--[@B16]\]. It has also been increasingly observed that the therapeutic efficacy of MSC therapy is not dependent on the engraftment of MSC at the site of injury or differentiation capability of the transplanted MSC \[[@B17]--[@B20]\], essentially eliminating the need for MSCs to be in the vicinity of their target tissue or to differentiate to exert a therapeutic effect. To reconcile this discrepancy between the therapeutic efficacy of MSC and the lack of MSC engraftment or differentiation at the site of injury, it was proposed that MSCs exert their therapeutic effects through secreted trophic mediators. The general acceptance of this proposal is reflected in the MSC clinical trials of 2010 in which 65 of the 101 clinical trials were rationalized on the trophic secretion of MSCs while only 36 were based on the differentiation potential of MSCs \[[@B21]\]. This paradigm shift in the therapeutic mechanism of MSC from one based on cell engraftment, differentiation and replacement to one based on secretion and paracrine signaling could potentially engender the development of biologic instead of cell-based therapeutics.

In 2008, our group demonstrated that intravenous administration of a single bolus of culture medium conditioned by human embryonic stem cell-derived MSCs (hESC-MSCs) reduced relative infarct size in a pig and mouse model of ischemia/reperfusion injury \[[@B22]\]. By molecular weight fractionation of this conditioned medium (CM), we demonstrated that the active component had a presumptive size of 50--200 nm \[[@B22]\]. Using size exclusion high performance liquid chromatography (HPLC), we purified a population of homogenously sized particles that have the biophysical parameters of exosomes, namely, a hydrodynamic radius of 55--65 nm and a flotation density in sucrose of 1.10--1.18 g/mL. We subsequently demonstrated that this exosome population alone could reduce infarct size by \~40% in a mouse model of myocardial ischemia/reperfusion injury and therefore was the therapeutic agent in the secretion of mesenchymal stem cells \[[@B23]\]. Therapeutic exosomes are also found to be secreted by primary MSC cultures \[[@B24]\] and myc-immortalized hESC-MSCs \[[@B25]\]. The exosomes have exosome-associated proteins such as the tetraspanin proteins, CD9 and CD81, Alix, Tsg101, and RNA that consists primarily of short RNAs of less than 300 nt. Some of these RNAs are microRNAs that are predominantly premicroRNAs \[[@B26]\].

As cells for example, H9C2 cardiomyocytes \[[@B26]\] readily internalized MSC exosomes, possibly by endocytosis, the exosome cargo of protein and RNA could be delivered across plasma membranes into cells. This diverse exosome cargo could, in principle provide a molecular basis for the therapeutic efficacy of MSC secretion in treating a diverse range of diseases (e.g., acute myocardial infarction, endstage ischemic heart disease, or prevention of vascular restenosis), osteogenesis imperfecta (OI) or brittle bone disease, amyotrophic lateral sclerosis (ALS), lysosomal storage diseases (e.g., Hurler syndrome), steroid refractory graft versus host disease (GVHD), periodontitis and bone fractures \[[@B12]\]. The cargo complexity of exosome could also provide a rationale for the efficacy of exosomes in treating complex tissue injuries such as myocardial ischemia/reperfusion injury that involves multiple tissues and targets.

We believe that the individual components in exosome cargo are not equally or sufficiently efficacious in ameliorating tissue injury. We hypothesize that the therapeutic efficacy of MSC exosome against a specific injury is derived from the synergy of a select permutation of individual exosome components. To identify optimal permutation of biochemical activities for effective amelioration of myocardial ischemia/reperfusion injury and other injury, we are now systematically analyzing each of the candidate biochemical activities in MSC exosomes to first assess each activity and its potential to ameliorate injury.

In this paper, we focused on the proteome of exosomes to identify candidate proteins or protein complexes that could drive their efficacy against diverse disease targets, the proteome of these purified exosomes was profiled here by mass spectrometry and antibody array, and found to contain 857 unique gene products (<http://www.exocarta.org/>). These proteins were distributed over a wide array of biochemical and cellular processes such as communication, structure and mechanics, inflammation, exosome biogenesis, tissue repair and regeneration and metabolism (Lai et al., submitted) consistent with the reported proteome complexity of MSC exosomes.

A predominant feature of MSC exosome proteome was the presence of all seven *α* and seven *β* chains of the 20S proteasome, and the three beta subunits of "immunoproteasome" which were identified with very high confidence level by mass spectrometry. These observations were indicative of fully assembled and possibly functional 20S proteasome and immunoproteasome which constitute the catalytic core of the 26S proteasome. The presence of 20S proteasome in exosomes also provides a mechanism for cellular extrusion of the relatively large intact 20S proteasomes as extracellular, circulating proteasome \[[@B27]--[@B31]\]. Circulating proteasomes are functionally active and could degrade small peptides. They have been shown to correlate with disease state or progression demonstrating that extracellular proteasomes have important physiological and pathological functions \[[@B27]--[@B31]\]. It has been postulated that these extracellular proteasomes are important in degrading soluble peptides in extracellular fluids and modulating potentially pathogenic protein aggregation such as Alzheimer\'s amyloid plaques \[[@B32]\]. A key to understanding the functions of these extracellular proteasomes will be to determine how and when cells extrude proteasome. As the level of circulating proteasome does not correlate with lactate dehydrogenase it is unlikely that extracellular proteasomes are products of cell lysis \[[@B33]\].

In this paper, we demonstrated that MSC exosomes contained functional 20S proteasomes and its presence correlated with a modest but significant reduction in oligomerized protein in a mouse model of myocardial infarction. Therefore, 20S proteasome is a candidate exosome protein that could synergize with other constituents to ameliorate tissue damage.

2. Materials and Methods {#sec2}
========================

2.1. Preparation of Exosomes {#sec2.1}
----------------------------

Exosomes were purified from culture medium conditioned by huES9.E1, human ESC-derived mesenchymal stem cells \[[@B34]\] by HPLC as previously described \[[@B24], [@B35]\]. Briefly, CM collected from MSCs culture was concentrated 50x by tangential flow filtration (TFF) using a membrane with a 100 kDa MWCO (Sartorius, Goettingen, Germany). CM was fractionated by high performance liquid chromatography (HPLC) (TSK Guard column SWXL, 6 × 40 mm and TSK gel G4000 SWXL, 7.8 × 300 mm, Tosoh Corp., Tokyo, Japan). Exosomes were collected from the first peak of the elution and concentrated using 100 kDa MWCO filter (Sartorius). Exosomes were filtered with a 0.22 *μ*m filter and stored in −20°C freezer until use.

2.2. LC MS/MS {#sec2.2}
-------------

Three independent preparations (biological replicates) of HPLC-purified exosomes were analyzed by LC-MS/MS over nine months using three different methods of tryptic digestion. In each preparation, about 2 mL proteins of dialyzed exosomes were used. In the first preparation, the sample was in-solution trypsin digested, that is, reduced, alkylated and tryptic digested as described \[[@B36]\]. After desalting using Sep-Pak C-18 SPE cartridge (Waters, Milford, MA, USA), the tryptic digest was directly analyzed with LC-MS/MS twice (two injections) without further fractionation. In the second preparation, the sample was separated by SDS-PAGE and the gel lane was cut into 8 slices for in gel digestion. Tryptic peptides from each gel slice were analyzed by LC-MS/MS. In the third preparation, the sample was tryptic digested and desalted. To reduce sample complexity, offline peptide fractionation was carried out with a HPLC system (Shimadzu, Japan) through a Polysulfoethyl SCX column (200 mm × 4.6 mm) (PolyLC, USA). Mobile phase A (5 mM KH4PO4 + 30% acetonitrile) and mobile phase B (5 mM KH4PO4 + 30% acetonitrile + 350 mM KCl) at 1 mL/min. Eight fractions were collected, desalted, and dried with a vacuum centrifuge. All three independent replicates were analyzed by a LC-MS/MS system including a Shimadzu micro HPLC system coupled online to a LTQ-FT Ultra linear ion trap mass spectrometer (Thermo Electron, Bremem, Germany) fitted with a nanospray source. Injected peptides were trapped and desalted in a Zorvax 300SB-C18 enrichment column (5 mm × 03 mm, Agilent Technologies, Germany) and eluted into a nano-bored C18 packed column (75 *μ*m × 100 Å, Michrom Bioresources, Auburn, CA USA). A 90 minute gradient at a constant flow rate of 20 *μ*L/min with a splitter to an effective flow rate of 300 nl/min was used to elute the peptides into the mass spectrometer. The LTQ was operated in a data-dependent mode by performing MS/MS scans for 8 of the most intense peaks from each MS scan in the FTMS. For each experiment, all MS/MS (dta) spectra of each replicate were combined into a single mascot generic file by a home-written program. Protein identification was achieved by searching the combined data against the IPI human protein database (version 3.34; 69,164 sequences, 29,064,825 residues) via an in-house Mascot server (Version 2.2.04, Matrix Science, UK). The search parameters were a maximum of 2 missed cleavages using trypsin; fixed modification was carbamidomethylation of cysteine and variable modification was oxidation of methionine. The mass tolerances were set to 10 ppm and 0.8 Da for peptide precursor and fragment ions, respectively. Protein identification was accepted as true positive if two different peptides were found to have scores greater than the homology scores.

2.3. Antibody Array {#sec2.3}
-------------------

500 *μ*L of non-conditioned media and exosomes were assayed for the presence of cytokines andother proteins using RayBio Biotin Label-based Human Antibody Array I according to manufacturer\'s instructions (RayBio, Norcross, GA). The cytokines and other proteins were considered to be present in the exosomes if the signal intensity was 2 fold higher (*P* \< 0.05) than that in non-conditioned medium.

2.4. Western Blot Hybridization {#sec2.4}
-------------------------------

3 *μ*g of conditioned medium or exosomes were separated on 4--12% SDS-polyacrylamide gels and electroblotted onto a nitrocellulose membrane. The membrane was transferred to the membrane holder of SNAP i.d. system (Millipore, Billerica, MA), blocked and incubated with 1 : 200 diluted mouse anti-20S proteasome *α*1--7. The blot was then incubated with a 1 : 1250 diluted horseradish peroxidase-coupled goat anti-mouse IgG. All antibodies were obtained from Santa Cruz Biotechnology, Santa Cruz, CA. The blot was then incubated with HRP-enhanced chemiluminescent substrate (Thermo Fisher Scientific Inc., Waltham, MA, USA) and then exposed to X-ray film.

2.5. 20S Proteasome Enzymatic Assay {#sec2.5}
-----------------------------------

The proteasome activity was measured using a 20S proteasome activity assay kit (Millipore) based on detection of the fluorophore 7-Amino-4 methylcoumarin (AMC) after cleavage from the labeled substrate LLVY-AMC by 20S proteasome in the presence or absence of lactacystin, a specific 20S proteasome inhibitor. Briefly, 4 *μ*g of exosome was incubated with a reaction buffer containing LLVY-AMC in the presence or absence of 25 *μ*M lactacystin. The samples and AMC standards were incubated at 37°C and fluorescence intensity at Ex/Em = 380/460 nm was monitored for 2 hours.

2.6. Animals and Experiments {#sec2.6}
----------------------------

Male C57Bl6/J (10--12 wks, 25--30 g) mice were obtained from Jackson Laboratory (Bar Harbor, USA). Mice received standard diet and water ad libitum. Myocardial infarction was induced between 8 am and 1 pm by left coronary artery ligation, just below the left atrial appendage. All animal experiments are performed in accordance with the national guidelines on animal care and with prior approval by the Animal Experimentation Committee of Utrecht University, The Netherlands.

2.7. Myocardial Infarction *In Vivo* {#sec2.7}
------------------------------------

Mice were anesthetized with a mixture of Fentanyl (Jansen-Cilag) 0.05 mg/kg, Dormicum (Roche) 5 mg/kg and medetomidine 0.5 mg/kg through an intraperitoneal injection. Core body temperature was maintained around 37°C during surgery by continuous monitoring with a rectal thermometer connected to an automatic heating blanket. Mice were intubated and ventilated (Harvard Apparatus Inc.) with 100% oxygen. The left coronary artery (LCA) was ligated for 30 minutes using an 8-0 Ethilon (Ethicon) with a section of polyethylene-10 tubing placed over the LCA. Ischemia was confirmed by bleaching of the myocardium and ventricular tachyarrhythmia. Five minutes before reperfusion, mice were intravenously infused with 200 *μ*L saline-diluted exosome containing 0.4 *μ*g protein via the tail vein. Control animals were infused with 200 *μ*L saline. Reperfusion was initiated by releasing the ligature and removing the polyethylene-10 tubing. Reperfusion of the endangered myocardium was characterized by typical hyperemia in the first few minutes. The chest wall was closed and the animals received subcutaneously atipamezole (Antisedan, Pfizer) 2.5 mg/kg, flumazenil (Anexate, Roche) 0.5 mg/kg and buprenorphine (Temgesic, Schering-Plough) 0.1 mg/kg. At 15 min, 1 hour, 24 hours, or 3 days after reperfusion (*n* = 4/group/time point), animals were sacrificed and the area at risk was excised for protein extraction. LCA ligation in mice results in anterior wall ischemia, while the septal wall is perfused by a septal coronary artery that originates separately from the sinus valsalva. The entire anterior wall of the left ventricle below the level of ligation was excised for area at risk protein extraction.

2.8. Antioligomer Dot Plot {#sec2.8}
--------------------------

Protein was extracted from area at risk of 30 min LCA ligated mouse heart treated with exosome or saline after 15 minutes, 1 hour, 1 day, and 3 days reperfusion using a cell extraction buffer from Biovision, Mountain View, CA, USA according to manufacturer\'s instruction. Four animals were used at each time point in the exosome or saline treatment arm. One *μ*g of each sample was applied on a nitrocellulose membrane, air dried, stained with Ponceau S, quantified using Image Lab (Bio-rab Laboratories) and destained. The membrane was then blocked with 10% non-fat dry milk TBST solution, incubated with a 1 : 1000 diluted rabbit anti-oligomer antibody (Invitrogen, Carlsbad, CA) for 2 hours and washed 3 times with TBST. This was followed by one hour incubation with a 1 : 2000 diluted horseradish peroxidase-coupled donkey anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA). 3 washes with TBST and incubation with HRP-enhanced chemiluminescent substrate (Thermo Fisher Scientific Inc., Waltham, MA USA). The signal was scanned using ChemiDoc System (Bio-rab Laboratories, Philadelphia, PA) and quantified using Image Lab (Bio-rab Laboratories). The signal was normalized against the intensity of the Ponceu S stain.

2.9. Sucrose Density Gradient Equilibrium Centrifugation {#sec2.9}
--------------------------------------------------------

To generate the sucrose density gradient for centrifugation, 14 sucrose solutions with concentrations from 22.8 to 60% were prepared and layered sequentially in an ultracentrifuge tube (Beckman Coulter Inc., CA, USA) starting with the most concentrated solution. Exosome or human plasma was loaded on top before ultracentrifugation for 16.5 h at 200 000 g, 4°C in a SW60Ti rotor (Beckman Coulter Inc.). After centrifugation, 13 fractions of 330 *μ*L each were collected sequentially starting from the top of the gradient. The densities of each fraction were determined by weighing a fixed volume. For pretreatment with detergent-based lysis buffer (Cell Extraction Buffer, Biovision), exosome was incubated with an equal volume of the lysis buffer containing protease inhibitors (Halt Protease Inhibitor Cocktail, Thermo Fisher Scientific) for 30 min on ice before loading on the sucrose density gradient. For subsequent western blot hybridization, 20 *μ*L samples from each fraction were used. The mouse anti-CD63, -CD9, -CD81, and -CD59 antibodies, were obtained from Santa Cruz Biotechnology, Santa Cruz, CA, USA (1 : 60 dilution).

2.10. Liquid Phase Isoelectric Focusing {#sec2.10}
---------------------------------------

Liquid phase isoelectric focusing was performed using MicroRotofor, Liquid-Phase IEF Cell, from Bio-Rad (Bio-Rad Laboratories). 80 *μ*g exosome was added to 3 mL of 0.5% Bio-Lyte 3/10 Ampholyte (Bio-Rad Laboratories, diluted with PBS). The sample was loaded into the focusing chamber with 0.1 M phosphoric acid on anode and 0.1 M Sodium Hydroxide on cathode. Isoelectric focusing was performed for 215 min at 1 W constant power. The samples were then collected using vacuum suction into 10 fractions. The pH of each fraction was determined using pH indicator paper (Macherey-Nagel, Bethlehem, PA, USA) before concentrating to 25 *μ*L using 100 kDa MWCO filter (Millipore).

2.11. Cholera Toxin B Precipitation {#sec2.11}
-----------------------------------

50 *μ*L of each human plasma fraction from sucrose gradient density equilibrium ultracentrifugation as described above was incubated with 0.005 *μ*g biotinylated-cholera toxin B conjugated to streptavidin-conjugated magnetic beads (Invitrogen Corporation) for 30 min with gentle shaking followed by 30 min incubation The supernatant was then discarded and the magnetic beads were washed thrice with 0.1% BSA/PBS before incubating with 50 *μ*L of detergent-based lysis buffer (Cell Extraction Buffer, Biovision) on ice for 10 min. The lysate was then collected and biotinylated by incubating with 4 *μ*L 2.5 mM EZ-Link Sulfo-NHS-LC-LC-Biotin (Thermo Fisher Scientific) for 30 min with gentle shaking. The remaining reactive biotin was then quenched by adding 100 mM glycine buffer. The biotinylated lysate was then incubated with 5 *μ*L anti-CD81 or -20S *α*1--7 conjugated magnetic beads (Invitrogen Corporation) for 30 min with gentle shaking. The supernatant was then discarded and the magnetic beads were washed thrice with 0.1% BSA/PBS before incubating with 50 *μ*L of 1 : 5000 diluted HRP-conjugated streptavidin (Biolegend, San Diego, CA, USA) for 15 min at room temperature with gentle shaking. Finally the supernatant was discarded and the magnetic beads were washed thrice with 0.1% BSA/PBS. The amount of bound HRP was determined using Amplex UltraRed Reagent (Invitrogen Corporation) according to manufacturer\'s instruction.

3. Results {#sec3}
==========

3.1. Proteomic Profiling of Exosome {#sec3.1}
-----------------------------------

Proteomic profiling using mass spectrometry and antibody array approaches were performed as previously described \[[@B24], [@B35], [@B37]\] on three or one independent preparations of HPLC-purified exosomes, respectively. Mass spectrometric analysis of the three exosome preparations identified 379, 432, and 420 proteins, respectively (please refer to Supplementary File 1 for the LC MS/MS raw data). Of these, 154 (\~20%) were present in all three preparations, 157 (\~20%) were present in two while 455 (\~59%) were present in only one ([Figure 1(a)](#fig1){ref-type="fig"}). These analyses were subsequently validated by western blot hybridization or biochemical assays using either the three exosome preparations used in the mass spectrometric analysis or other independently prepared exosomes. Several proteins determined by mass spectrometry to be present in two or one of the three preparations were found to be present in these or other subsequent preparations by either western blot hybridization or biochemical assays. For example, PFKFB3 and PGK were detected in only one and two of the three batches, respectively. However, when tested by western blot hybridization or biochemical assays, both proteins were found to be present in two or more of the three preparations and also subsequent exosome preparations (data not shown). This indicated that the three independent exosome preparations analyzed by LC-MS/MS within nine months interval using three different sample preparation methods were complementary to each other in identifying different sets of low abundant proteins or our selection criteria were too stringent. To ensure a more comprehensive coverage of the exosome proteome, we combined the 3 sets of mass spectrometry data. The analysis of the exosome proteome by antibody array identified 101 proteins of which 10 were also detected by mass spectrometry analysis ([Figure 1(b)](#fig1){ref-type="fig"}). By combining the results from mass spectrometry and antibody array, we determined that the exosome proteome has a total of 857 proteins ([Table 1](#tab1){ref-type="table"}) and this dataset has been deposited at <http://www.exocarta.org/>. In [Table 1](#tab1){ref-type="table"}, the regular font symbols represent the proteins identified by LC MS/MS; the underline symbols represent the proteins identified by antibody arrays; the bold and underline symbols represent the proteins identified by both LC MS/MS and antibody arrays; and lastly the grey shaded symbols represent the proteins that were found to be present in at least 50% of exosomes characterized \[[@B38]\]. Of these 857 proteins, 320 were found in the 739 proteins previously identified in the unfractionated conditioned medium \[[@B24], [@B35]\] ([Figure 1(c)](#fig1){ref-type="fig"}). The remaining 537 proteins in the exosome were detected only when HPLC-purified exosomes were used. Since exosomes constituted about 10% of the total proteins in the conditioned medium \[[@B35]\], we postulated that many of the exosome proteins were masked by the more abundant nonexosome proteins in the conditioned medium.

Based on 15 proteomic analyses carried out on exosomes purified from cultured cells and from biological fluids by different groups, Thery et al. had observed that a set of about 17 proteins, namely glyceraldehyde 3-phosphate dehydrogenase (GAPDH), pyruvate kinase (PK), eukaryotic translation elongation factor 1A1 (EEF1A1), milk fat globule EGF factor 8 protein (MFGE8), tetraspanins, 14-3-3 proteins, G*α* proteins, clathrin, Alix (PDCD6IP), MHC class1, annexins (ANX), Rab proteins, ezrin(VIL2), radixin(RDX) and moesin (MSN)(ERM), actin, tubulin, HSP70, and HSP90 were found to be present in at least 50% of the exosomes that were characterized \[[@B38]\]. Not unexpectedly, most of these proteins were also found in the proteome of the HPLC-purified MSC exosomes ([Table 1](#tab1){ref-type="table"}). Also consistent with the endosomal origin of exosomes, we detected the presence of endosome-associated proteins such as Alix (PDCD6IP) and Rab ([Table 1](#tab1){ref-type="table"}).

To better understand the biological significance of the proteins in the exosomes, we had previously performed functional clustering of the 857 proteins into biological processes using PANTHER (protein analysis through evolutionary relationships) analytical software \[[@B40], [@B41]\] (Lai et al.; submitted) The observed frequency of genes from the exosome proteome in each biological process was compared with the reference frequency of 25431 *Homo sapiens*gene list in the NCBI database for that biological process. The 857 gene products could be clustered into 32 biological processes that were over-represented (*P* \< 0.001) and 3 that were under-represented (*P* \< 0.001) (Lai et al.; submitted). Many of these biological processes are consistent with activities associated with exosome biology for example, communication, cellular motility, inflammation, and exosome biogenesis. One predominant biological process that could not be definitively associated with exosome biology is proteolysis (*P* = 3.76 × 10^−10^) and of the unique genes clustered in this process, \~22% (17 out of 78) encode for peptides in the 20S proteasome or immunoproteasome. To ensure the robustness of this observation, examination of the 3 sets of mass spectrometry datasets revealed that with only one exception of PSMB5 in the first exosome preparation, all the 14 peptides of 20S proteasome were detected with very high confidence in all three exosome preparations as demonstrated by the Mascot search results, number of identified peptides with score higher than homology or identity scores, as well as the MS/MS spectra and fragment ions assignment of unique identified peptides (Supplementary data 1--7).

3.2. Presence of 20S Proteasome in MSC Exosome {#sec3.2}
----------------------------------------------

Mass spectrometry analysis of MSC exosomes not only detected the presence of all seven *α*- (PSMA1--7) and all seven *β*-subunits (PSMB1--7) of the 20S core particle with very high confidence (See Supplementary Material available online at doi:10.1155/2012/971907 for the representative spectra, number of peptide detected, and the peptide score of them), but also the three beta subunits of "immunoproteasome," PSMB8 (*β*5i or LMP7), PSMB9 (*β*1i or LMP2), PSMB10 (*β*2i or LMP10) gene product \[[@B42]\]. To form the 26S proteasome, the 20S core particle must be complemented by other peptides. Although some of these peptides such as PSMC5, PSMD6, PSMD7, PSMD11, and PSMD14 were present, they were not sufficient to form the 26S proteasome. The presence of some of the 20S proteasome peptides was further confirmed by western blot hybridization ([Figure 2(a)](#fig2){ref-type="fig"}). As exosomes are known to have a typical density range of 1.10 to 1.18 gmL^−1^ that could be resolved on sucrose gradients \[[@B43]\], we checked whether these 20S proteasome subunits have the typical exosome flotation density and postulated that the flotation densities of the 20S proteasome subunits would be different before and after release from such vesicles by a detergent-based buffer. Fractionation of exosomes or exosomes pretreated with a detergent-based lysis buffer on a sucrose density gradient by equilibrium ultracentrifugation revealed that 20S proteasome subunits had a similar flotation density as that of exosome-associated proteins, namely, CD9, CD81, CD59, and CD63. All of them had an exosomes-like flotation density of 1.10--1.18 g/mL ([Figure 2(b)](#fig2){ref-type="fig"}). Pretreatment with a detergent-based cell lysis buffer decreased the apparent flotation densities of these proteins. Liquid phase isoelectric focusing of exosomes further revealed that 20S proteasome had a similar protein isoelectric point (pI) as that of exosome-associated CD9 ([Figure 2(c)](#fig2){ref-type="fig"}). Together the exosome-like flotation density and pI of the 20S proteasome suggested that the 20S proteasome was associated with exosomes and not a contaminant of exosome preparation.

3.3. Enzymatic Activity of 20S Proteasome in MSC Exosome {#sec3.3}
--------------------------------------------------------

The presence of all seven *α*- and all seven *β*-subunits of the 20S core particle indicates that MSC exosomes contain intact 20S proteasome complexes and therefore 20S proteasome enzymatic activity. To test if exosomes contain functional 20S proteasome, purified MSC exosomes were incubated with a fluorophore-labeled peptide, LLVY-AMC (a substrate for the chymotrypsin-like activity; AMC, 7-amido 4-methylcoumarin) \[[@B44]\], that upon cleavage by 20S proteasome released fluorescent AMC. The fluorescence produced by the released AMC would be directly proportional to the proteasome activity. Based on this assay, the 20S proteasome enzymatic activity in MSC exosomes was determined to be 5.00 *μ*U/*μ*g protein where one unit (U) enzyme activity is defined as the activity to generate 1 *μ*mole product per minute at 37°C. This degradation was inhibited by lactacystin, a proteasome-specific inhibitor ([Figure 2(d)](#fig2){ref-type="fig"}).

3.4. Exosome Proteasome Reduced Misfolded Proteins *In Vivo* {#sec3.4}
------------------------------------------------------------

To determine if exosome proteasome can reduce misfolded or aberrant proteins *in vivo* in a disease model and possibly contribute to a therapeutic outcome, we measured the accumulation of misfolded proteins in heart tissue of a mouse model of myocardial ischemia/reperfusion injury with and without exosome treatment.

This model is most appropriate for our aim as accumulation of misfolded proteins has been recognized as an important contributor to tissue damage during myocardial ischemia/reperfusion injury \[[@B45]--[@B49]\] (reviewed \[[@B50]\]) and we have previously shown that exosome treatment resulted in extensive cardioprotection \[[@B23]\]. Furthermore, in our hands, the area at risk in this mouse model is also highly reproducible \[[@B23], [@B24], [@B51]--[@B53]\].

To determine if exosome could reduce the amount of misfolded proteins, we used a conformation-dependent antibody \[[@B54]\] to quantify the amount of misfolded proteins in the area at risk of ischemic mouse heart after 15 min, one hour, one day and three days reperfusion. The level of denatured or misfolded protein was assayed using an antibody against oligomers. Denatured or partially unfolded proteins tend to self-associate to form high molecular aggregates such as oligomers and these oligomers have a common structure that is independent of amino acid sequence \[[@B55]\]. An antibody known as A11 that was raised against synthetic A*β* oligomers was found to specifically recognize this common structure present in misfolded protein oligomers but did not recognize monomers or mature fibers of proteins or peptides \[[@B55]\]. It will react with soluble A*β*40 oligomers and does not react with soluble low molecular weight A*β*40 or A*β*40 fibrils.

Using this antibody, we found that those mice treated with exosome had a modest but significantly lower level of misfolded proteins (*P* = 0.037) (*n* = 4 per time point) 1 day after reperfusion compared with those saline treated controls (*n* = 4 per time point) ([Figure 3](#fig3){ref-type="fig"}). This demonstrated that MSC exosome has the potential to reduce misfolded proteins *in vivo* and may contribute to the exosome-mediated cardioprotection.

3.5. Association of Plasma 20S Proteasome with Exosome {#sec3.5}
------------------------------------------------------

Although our experimental observations strongly supported the presence of functional 20S proteasome in MSC exosomes, the association of 20S proteasome with exosomes could be a culture artifact contaminant. To test this possibility, we determined if circulating 20S proteasome in human plasma is associated with exosomes. 20S proteasomes are widely reported to be present in plasma \[[@B27]--[@B31]\] and we confirmed this by immunoblotting plasma for the presence of proteasome subunits ([Figure 4(a)](#fig4){ref-type="fig"}). Fractionation of plasma on a sucrose density gradient revealed that the plasma 20S proteasome fractionated at the flotation density of exosome that is, 1.10--1.18 g/mL ([Figure 4(a)](#fig4){ref-type="fig"}). CD81, a tetraspanin protein commonly found on exosome membrane also floated at this density. Each of the fractions was then extracted with cholera toxin B chain (CTB) which binds GM1 ganglioside, a glycolipid found to be enriched in the membrane of exosomes \[[@B56]\] and also MSC exosomes (unpublished data). CTB together with cholera toxin A chain forms the cholera toxin. Cholera toxin enters the cytosol by binding GM1 ganglioside through CTB \[[@B57]\]. This cellular entry of cholera toxin is a well characterized highly specific receptor mediated pathway \[[@B58]\]. The CTB extract was then assayed by ELISA for 20S proteasome subunits and CD81. 20S proteasome subunits and CD81 were both found to be present in the CTB extraction ([Figure 4(b)](#fig4){ref-type="fig"}). These observations demonstrated that plasma 20S proteasome colocalized with CD81 in GM1 ganglioside-enriched complex that floats at 1.10--1.18 g/mL and that at least some of the circulating proteasomes in the plasma are associated with exosomes. The presence of 20S proteasome in MSC exosomes and plasma exosomes together implicated exosome as a normal physiological conduit for cellular extrusion of 20S proteasome.

4. Discussion {#sec4}
=============

In this paper, we investigated the proteome of MSC exosome to identify candidate proteins or protein complexes that could contribute to their therapeutic efficacy in ameliorating myocardial ischemia/reperfusion injury or other pathological conditions. We hypothesize that this therapeutic efficacy against a complex injury is likely to be derived from the synergy of a select permutation of individual exosome components rather than a single component. To elucidate this permutation which may include proteins, RNA and other molecules, we focused first on the proteins by elucidating the exosome proteome to identify candidate proteins or protein complexes that have the biochemical potential to elicit a therapeutic response.

The proteome of 3 independently prepared, HPLC-purified ESC-derived MSC exosome using mass spectrometry and cytokine array were analyzed and 857 proteins were identified. We have previously reported that 739 proteins were profiled in hESC-MSC conditioned medium using LTQ-FT mass spectrometer. These proteins included many proteins commonly found in other exosomes. The proteome of MSC exosomes contained a diverse array of proteins. Clustering of these proteins according to their functions suggested that the exosome has the potential to drive many biological processes (Lai et al., submitted). This is consistent with the reported efficacy of MSCs in treating a myriad of diseases such as cardiovascular diseases (e.g., acute myocardial infarction, endstage ischemic heart disease, or prevention of vascular restenosis), osteogenesis imperfecta (OI) or brittle bone disease, amyotrophic lateral sclerosis (ALS), lysosomal storage diseases (e.g., Hurler syndrome), steroid refractory Graft versus Host Disease (GVHD), and periodontitis and bone fractures \[[@B12]\].

A significant fraction of proteins in MSC exosomes are involved in the highly regulated and complex intracellular membrane trafficking and sorting through the biosynthetic and endocytotic pathways \[[@B59]\], and these processes probably reflect the biogenesis of exosomes. In fact, many of the proteins in these processes constitute a common set of proteins found in exosomes from different cell sources \[[@B60]\]. However, the biological significance of the other proteins remains to be uncovered. Exosomes have been implicated in an increasing number of important physiological and pathological processes such as disposal of unwanted protein \[[@B61]\], antigen presentation \[[@B43]\], genetic exchange \[[@B62]\], immune responses \[[@B38], [@B63]\] and tumor metastasis \[[@B38], [@B63]--[@B67]\]. Whether the proteome of MSC exosomes could sustain such processes remains to be determined.

Proteasome subunits have been previously reported to be present in exosomes \[[@B62], [@B68]--[@B70]\] but this is the first time that mass spectrometry analysis of exosome proteome had detected the entire protein complement of a 20S proteasome with very high confidence. In addition, we also demonstrated that exosome had the lactacystin-sensitive proteolytic activity of 20S proteasome. Since decreased proteasome activity resulting in accumulation of misfolded proteins has been recognized as an important contributor to tissue damage during myocardial ischemia/reperfusion injury \[[@B45]--[@B49]\] (reviewed \[[@B50]\]) and MSC exosomes reproducibly reduce IS/AAR by \~40% in a mouse model of myocardial ischemia/reperfusion injury \[[@B23], [@B24], [@B53]\] we tested if cardioprotective MSC exosomes exert some of their therapeutic effects through proteolytic degradation of misfolded proteins. The level of denatured or misfolded protein was assayed using an antibody against oligomers. Using this antibody, we demonstrated that accumulation of misfolded proteins or oligomers was reduced in the heart tissues of a mouse model of myocardial ischemia/reperfusion injury that had been treated with MSC exosomes. This positive correlation between exosome-mediated decreased accumulation of misfolded proteins and exosome-mediated reduction in IS/AAR supports a therapeutic role the 20S proteasome in MSC exosome.

20S proteasome is responsible for the degradation of about 90% of all intracellular oxidatively damaged proteins \[[@B71]\] and reduced proteasomal activity has been postulated to be a contributing factor in the pathogenesis of aging-related neurodegenerative diseases such as Alzheimer\'s disease and Parkinson\'s disease \[[@B72], [@B73]\] or cardiovascular disease \[[@B74]--[@B76]\]. The presence of all seven *α* and *β* subunits of the 20S proteasome, the three beta subunits of "immunoproteasome" and validation of 20S proteasome enzymatic activity in the exosomes *in vitro* and *in vivo* suggested that the cardioprotective activity of MSC exosomes \[[@B35]\] could be partly attributed to the presence of 20S proteasome. This further implied that MSC exosomes have the potential to therapeutically correct for proteasome insufficiency. Many debilitating neurodegenerative diseases such as Alzheimer\'s, Parkinson\'s or prion disease that are caused by accumulation of denatured or misfolded proteins could thus be alleviated by MSC exosomes carrying functional proteasomes. The use of exosomes as a delivery vehicle for proteasome has the added advantage of being able to transcend the blood-brain-barrier. This barrier is the main cause in the intractability of neurodegenerative diseases to medical intervention. Unlike most conventional drugs, exosomes could cross the blood-brain-barrier as demonstrated by the recent knockdown of the gene target in the brain by exosomes loaded with exogenous siRNA \[[@B77]\].

The presence of 20S proteasome in MSC exosomes also suggested that cells extruded 20S proteasome through exosomes. Consistent with this, we observed that plasma proteasomes had the flotation density (1.10--1.19 g/mL) and pI of exosomes, and were associated with GM1 gangliosides, a glycolipid found to be enriched in the membrane of exosome \[[@B78]\]. This finding supported our hypothesis that cellular extrusion of 20S proteasomes via exosomes is a normal physiological process.

Together this study demonstrated that MSC and plasma exosomes contain functional 20S proteasome, and cells secrete proteasome via the exosome pathway. MSC exosomes could reduce misfolded proteins in the heart after ischemia/reperfusion injury suggesting that they could also be used to alleviate diseases precipitated by accumulation of denatured proteins such as Alzheimer\'s disease, Parkinson\'s disease or prion disease.

In conclusion, MSC exosome has functional 20S proteamsomes and its presence correlated with a modest but significant reduction in oligomerized protein in a mouse model of myocardial infarction. Therefore, 20S proteasome is a candidate exosome protein that could synergize with other constituents in the exosome to ameliorate tissue damage.
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Supplementary material provides the raw data of the detected 20S proteasome in 3 independent batches of exosomes. Supplementary data 1 provides a summary of number of detected peptides in 3 independent batches of exosomes; Supplementary data 2--4 provide the raw data of detected 20S proteasome peptides in 3 independent batches of exosomes respectively; Supplementary data 5--7 provide the Mascot peptide view of unique 20S proteasome peptides in 3 independent batches of exosomes respectively.
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Click here for additional data file.
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![Exosome proteins. (a) Venn diagram of number of proteins detected by LC-MS/MS in 3 independent batches of exosomes, CM15, CM17, and CM18. There are 379, 432, and 420 proteins detected in CM15, CM17 and CM18, respectively. The combined protein number is 766. (b) Venn diagram shows the overlap of proteins detected by LC-MS/MS and antibody array. There are 101 proteins detected by antibody array in CM15. 10 of the 101 proteins detected are overlapping with proteins detected by LC-MS/MS. (c) Intersection of the 739 proteins previously identified in MSC conditioned medium versus the 857 proteins identified in purified exosomes.](IJPRO2012-971907.001){#fig1}

![20S proteasome in MSC exosome. (a) Western blot analysis of MSC conditioned medium (CM) and exosome (Exo) using an antibody specific for PMSA 1--7 peptides. (b) Protein analysis of exosome fractionated on a sucrose gradient density. Exosome or exosome pretreated with lysis buffer was loaded on a sucrose density gradient prepared by layering 14 sucrose solutions of concentrations from 22.8 to 60% (w/v) in a SW60Ti centrifuge tube and then ultracentrifuged for 16.5 h at 200 000 g, 4°C, in a SW60Ti rotor. The gradients were removed from the top and the density of each fraction was calculated by weighing a fixed volume of each fraction. The fractions were analyzed by western blot analysis for CD9, PSMA1--7, CD81, CD59, and CD63 in exosome (upper panel) and pretreated exosomes (lower panel). (c) pI of 20S proteasome and CD9 in exosome. Exosome sample was separated by liquid-phase isoelectric focusing into 10 fractions from pH1--14. Each fraction was then concentrated and analyzed by western blot analysis for CD9, PSMA1--7. (d) Proteasome activity in MSC exosome was determined using a commercially available proteasome activity assay kit as described in the Materials and Methods section. Proteasome activity was measured by the rate of degradation of a fluorogenic peptide in the absence or presence of lactacystin, a proteasome inhibitor. One unit (U) enzyme activity is defined as the activity to generate 1 *μ*mole product per minute at 37°C. Each bar represents mean ± SEM of 2 independent assays with each assay performed in triplicate. \**P* = 0.00023.](IJPRO2012-971907.002){#fig2}

![Exosome reduced oxidized protein *in vivo*. Myocardial ischemia/reperfusion injury was induced by ligation of the left coronary artery (LCA) for 30 min and subsequent reperfusion by releasing the ligation. Five minutes before reperfusion, mice (*n* = 4/group/time point) were intravenously infused with exosome or saline. At 15 min, 1 hour, 1 day, or 3 days after reperfusion, the animal was scarified and the area at risk (AAR) was excised and extracted for protein. One *μ*g of each sample was applied onto a nitrocellulose membrane, stained with Ponceau S, destained and probed with rabbit antioligomer antibody and a HRP reporting system as described in material and method. The intensity of the antibody binding was quantified using Image Lab and normalized against the intensity of Ponceau S staining. (a) Representative dot plots. (b) Each bar represented mean ± SEM of 4 animal.](IJPRO2012-971907.003){#fig3}

![Human plasma contained exosome-associated 20S proteasome. (a) Human plasma was loaded on a sucrose density gradient prepared by layering 14 sucrose solutions of concentrations from 22.8 to 60% (w/v) in a SW60Ti centrifuge tube and then ultracentrifuged for 16.5 h at 200 000 g, 4°C, in a SW60Ti rotor. 330 *μ*L fractions were removed sequentially from the top and the density of each fraction was calculated by weighing a fixed volume of each fraction. The fractions were analyzed by Western blot analysis for PSMA1--7. (b) Relative amount of CD81 and PSMA1--7 in plasma exosome. Exosomes which are known to have membrane enriched in GM1 gangliosides were isolated from the sucrose density gradient by the high affinity of GM1 gangliosides for cholera toxin B (CTB) chains conjugated to magnetic beads. The CTB extract was assayed by ELISA for the amount of PSMA1--7 and CD81. Each point represents mean ± SEM (*n* = 2).](IJPRO2012-971907.004){#fig4}

###### 

Proteomic profile of 3 independently prepared exosomes as determined by LC MS/MS and antibody arrays.

  ---------------- -------------- ---------------- ---------------- ------------------- ------------------ -------------- ----------------- --------------- ------------------
  A2M              C11orf59       COPS4            FBXW8            HNRNPA1             KRT16              [MMP3]{.ul}    PRR4              RPS3            TGFB2
  ABI3BP           C1orf78        COPS8            FEN1             HP                  KRT17              MOS            PRSS23            RPS4X           TGFBI
  ACAA2            C1R            CPS1             FER1L3           HPX                 KRT18              MPO            PSMA1             RPS5            TGM2
  ACAT2            C1S            CREG1            FGA              HRSP12              KRT19              MPZL1          PSMA2             RPSA            TGOLN2
  ACLY             C20orf114      CRIPT            FGB              **HSP90AA1**        KRT2               MRC2           PSMA3             RRAS2           [THBS1]{.ul}
  ACSL1            C3             CRTAP            [FGF16]{.ul}     **HSP90AB1**        KRT27              **MSN**        PSMA4             RTN4            **[THBS2]{.ul}**
  **ACTA1**        C5orf24        CSF1             [FGF18]{.ul}     **HSP90B1**         KRT28              MXRA5          PSMA5             RUVBL1          THY1
  **ACTA2**        C9orf19        [CSF2]{.ul}      [FGF19]{.ul}     **HSPA1A**          KRT3               MYADM          PSMA6             S100A11         [TIMP1]{.ul}
  **ACTB**         C9orf91        [CSF3]{.ul}      [FGFRL1]{.ul}    **HSPA1L**          KRT4               MYCBPAP        PSMA7             S100A13         [TIMP2]{.ul}
  **ACTG2**        CACNA2D1       CSPG4            FGG              **HSPA5**           KRT5               MYH14          PSMB1             [S100A8]{.ul}   [TIMP3]{.ul}
  ACTN1            CACNA2D4       CST4             FLG2             **HSPA6**           KRT6A              MYH9           PSMB10            S100P           TKT
  ACTN2            CALR           CTA-221G9.4      FLJ13197         **HSPA8**           KRT6B              MYL6B          PSMB2             SAA4            TLN1
  ACTN3            CAND1          CTBP2            FLJ22184         HSPB1               KRT6C              MYO1C          PSMB3             SASS6           TMBIM1
  ACTN4            CAP1           CTNNA1           FLJ32784         HSPD1               KRT7               [NBL1]{.ul}    PSMB4             SCAMP3          TMED10
  ACTR1A           CAPNS1         CTNNA2           FLNA             HSPG2               KRT72              NEFH           PSMB5             SCGB2A1         TMED9
  ACTR2            CAPZA1         CTNNB1           FLNB             HTRA1               KRT73              NEK10          PSMB6             [SCYE1]{.ul}    TMEM16B
  ACTR3            CASP14         CTNND1           FLNC             HYI                 KRT74              NID1           PSMB7             SDC1            TMEM2
  ADAM10           CAT            CTSG             FLOT1            **[ICAM1]{.ul}**    KRT76              NLRP8          PSMB8             SDC2            TMEM47
  ADAM9            CAV1           [CXCL16]{.ul}    FLOT2            [ICAM5]{.ul}        KRT77              NME1           PSMB9             SDC4            TMEM51
  ADAMTS12         CCDC129        [CXCL2]{.ul}     FLT1             IDH3B               KRT78              NOMO1          PSMC5             SDCBP           TNC
  AEBP1            CCDC64B        CXorf39          FN1              IFITM2              KRT79              NRAS           PSMD11            SEC14L4         [TNFRSF11B]{.ul}
  AFM              [CCL2]{.ul}    CYBRD1           FREM3            [IFNG]{.ul}         KRT8               [NRG2]{.ul}    PSMD14            SEMA5A          [TNFRSF12A]{.ul}
  AGRN             [CCL20]{.ul}   DBF4B            **[FST]{.ul}**   IFRD1               KRT80              [NRLN1]{.ul}   PSMD6             SEPT2           [TNFRSF1A]{.ul}
  AHCY             [CCL28]{.ul}   DCD              FTL              IFT140              KRT84              NRP1           PSMD7             SEPT7           TNFSF18
  AHNAK2           [CCL7]{.ul}    DCHS2            FUCA2            [IGF2R]{.ul}        KRT9               NT5E           PTGFRN            SERINC5         [TNFSF5]{.ul}
  AHSG             [CCR4]{.ul}    DCLK2            GALNT5           [IGFBP3]{.ul}       LACRT              [NTF5]{.ul}    PTK7              SERPINA1        TPBG
  AKR1B1           [CCR5]{.ul}    **[DCN]{.ul}**   GANAB            [IGFBP4]{.ul}       LAMA4              NUSAP1         PTPRK             SERPINB3        TPI1
  AKR7A2           CCT5           DCTN1            **GAPDH**        [IGFBP6]{.ul}       LAMB1              OBFC1          PTRF              SERPINE1        TRAP1
  ALB              CCT6A          DECR1            GAPDHS           **[IGFBP7]{.ul}**   LAMC1              ODZ3           PTTG1IP           SERPINE2        [TREM1]{.ul}
  [ALCAM]{.ul}     CD109          DEFA1            GARS             IGHA1               LAMP1              OFD1           **[PTX3]{.ul}**   SERPINF1        TREML2P
  ALDH2            CD151          DIP2B            GAS6             IGHA2               LAMP2              OPRM1          PXDN              SFN             TRIM40
  ALDH3A2          CD248          DIRAS2           [GDF1]{.ul}      IGHG1               LAP3               [OSM]{.ul}     PZP               SFRP1           TRIM41
  ALDH6A1          CD276          DKFZp686D0972    [GDF11]{.ul}     IGHG2               LCN1               OTC            QPCTL             [SFRP4]{.ul}    TSN
  ALDH7A1          CD44           [DKK1]{.ul}      [GDF3]{.ul}      IGHG4               LCN2               OXNAD1         QSOX1             SHANK3          TSNAX
  ALDH9A1          CD47           DKK3             [GDF5]{.ul}      IGHM                LDHA               OXTR           **RAB10**         SLAIN1          TSPAN14
  ALDOA            CD59           DMBT1            [GDF8]{.ul}      IGJ                 LDHAL6B            P4HB           **RAB11B**        SLC16A1         TSPAN4
  ALDOB            **CD63**       DNASE1L1         [GDF9]{.ul}      IGKC                LDHB               PAICS          **RAB14**         SLC16A3         TSPAN6
  ALDOC            **CD81**       DNPEP            GDI1             IGKV1-5             LEPRE1             PAN3           **RAB15**         SLC1A4          TSPAN9
  ALOX12P2         CD82           DPYS             GDI2             IGL@                LGALS1             PAPPA          **RAB1A**         SLC1A5          TSTA3
  [ANG]{.ul}       **CD9**        DPYSL2           [GFRA3]{.ul}     IGLV4-3             [LGALS3]{.ul}      PARP10         **RAB1B**         SLC22A2         TTLL3
  [ANGPTL2]{.ul}   CDC2L5         DSP              GLDC             IGSF8               LGALS3BP           PARP16         **RAB2A**         SLC25A10        TTN
  ANPEP            CDC42          DULLARD          GLUD1            [IL10]{.ul}         LGALS8             PARVG          **RAB33B**        SLC25A13        TTYH3
  **ANXA1**        CDH13          ECM1             **GNA13**        [IL11]{.ul}         LGR6               PC             **RAB35**         SLC2A1          **TUBA1A**
  **ANXA11**       CDIPT          [ED1]{.ul}       GNAI2            [IL13]{.ul}         [LIF]{.ul}         PCOLCE         **RAB39B**        SLC2A3          **TUBA1B**
  **ANXA2**        CDK5R2         EDG2             GNAL             [IL15RA]{.ul}       LMNA               PDCD6          **RAB5A**         SLC38A2         **TUBA1C**
  **ANXA2P1**      CEACAM8        EDIL3            GNAS             [IL17B]{.ul}        LOC124220          **PDCD6IP**    **RAB5B**         SLC38A3         **TUBB**
  **ANXA3**        CFB            EEA1             GNAT3            [IL17R]{.ul}        LOC283523          [PDGFA]{.ul}   **RAB5C**         SLC39A14        **TUBB2A**
  **ANXA4**        CFI            **EEF1A1**       GNB1             [IL19]{.ul}         LOC284297          [PDGFC]{.ul}   **RAB6A**         SLC3A2          **TUBB2C**
  **ANXA5**        CFL1           EEF1G            GNB2             [IL1F9]{.ul}        LOC388344          PDGFRB         **RAB7A**         SLC44A1         **TUBB3**
  **ANXA6**        CFL2           EEF2             GNB4             [IL1RAP]{.ul}       LOC389827          PDIA3          **RAB8A**         SLC44A2         **TUBB6**
  **ANXA7**        CFTR           EFEMP2           GNG12            IL1RAPL1            LOC442497          PEBP1          **RAB8B**         SLC7A10         UBA52
  AP1S1            CHMP2A         EHD1             GNPDA1           [IL1RL2]{.ul}       LOC653269          PFAS           RAC1              SLC7A5          UBB
  APEH             CHST12         EHD2             GOT2             [IL22RA1]{.ul}      LOC727942          PFKFB3         RAC2              SMARCA4         UBE1
  APOA1            CITED1         EHD4             GPC1             [IL23A]{.ul}        LOC728320          PFN1           RAD21             SMC1A           UBE2N
  APOE             CLASP2         EIF4A1           [GPC5]{.ul}      [IL3]{.ul}          LOC728378          PFN2           RALA              SORT1           UGP2
  APP              CLDN1          EMILIN1          GPI              [IL5]{.ul}          LOC730013          PGAM2          RAN               SPACA1          UNC13B
  ARF1             CLEC11A        ENG              GPR112           [IL6ST]{.ul}        LRP1               PGD            RAP1A             [SPARC]{.ul}    UNC45A
  ARF4             CLIC1          ENO1             GREM1            [IL7]{.ul}          [LRP6]{.ul}        PGK1           RAP1B             SPOCK1          VAMP3
  ARF5             CLIC6          ENO2             GRM2             [IL8]{.ul}          LRRFIP2            PGLYRP2        RAP1B             SPRY4           VANGL1
  ARHGAP18         CLPX           ENO3             GRM3             [INHBA]{.ul}        **[LTBP1]{.ul}**   PIGR           RAP2C             SPTAN1          **[VASN]{.ul}**
  ARHGAP23         CLSTN1         ENTPD4           GRM7             INHBB               LTBP2              PIP            RARRES1           SPTBN1          VAT1
  ARHGDIA          **CLTA**       ENTPD4;LOXL2     GSN              [INSR]{.ul}         LTF                **PKM2**       RASA1             SPTBN4          VCAN
  ARHGEF1          **CLTC**       EPB41L3          GSTM1            IQGAP1              LYAR               [PLAB]{.ul}    RASA4             SRGN            VCL
  ARL6IP5          **CLTCL1**     EPHA2            GSTM2            ITGA11              LYZ                [PLAU]{.ul}    RB1CC1            SRI             VCP
  ARMS2            CLU            [EPO]{.ul}       GSTM5            ITGA2               [MADH4]{.ul}       PLEC1          RCOR2             SRPX2           [VEGFC]{.ul}
  ARPC3            CMIP           [ESM1]{.ul}      GSTO1            ITGA3               MAMDC2             PLEKHG3        RDH5              ST6GALNAC6      VIL1
  ARPC4            CNGB1          ETFB             GSTP1            ITGA4               MAP1A              PLOD1          RFTN1             STAT1           **VIL2**
  ARPC5            COL12A1        F2R              GTPBP2           ITGA5               MAP2K6             PLOD2          RGN               STC1            VIM
  ASH1L            COL14A1        **[F3]{.ul}**    GYLTL1B          [ITGAL]{.ul}        MAP3K1             PLOD3          RHOC              STC2            VTI1A
  ASL              COL18A1        F8               [GZMA]{.ul}      ITGAV               MARCKS             PLP2           RMND5A            STOM            VTN
  ATP1A1           COL1A1         [FADD]{.ul}      H2AFV            ITGB1               MARCKSL1           PLSCR3         RNF123            STOML3          WDR49
  ATP1B3           COL1A2         FAH              H2AFX            ITGB5               MAT1A              PLTP           RNF40             STX12           WDR52
  ATP2B1           COL2A1         FAM108A1         HBB              ITIH2               MBD3               PLUNC          RPL10A            STX2            WNT5A
  ATP2B4           COL3A1         FAM129B          HBE1             ITIH4               MCC                PNO1           RPL12             SURF4           YBX1
  ATP5A1           COL4A1         FAM29A           HDAC5            ITPR2               MCM10              PODN           RPL15             SVEP1           **YWHAB**
  ATP5B            COL4A2         [FAM3B]{.ul}     HERC5            JUP                 MDH1               POLN           RPL18             SYT1            **YWHAE**
  ATP8B3           COL4A3         FAM64A           [HGF]{.ul}       KIAA0146            MDH2               POSTN          RPL23             SYT9            **YWHAG**
  ATRN             COL5A1         FAM71F1          [HGFR]{.ul}      KIAA0256            ME1                POTE2          RPL29             TAAR2           **YWHAQ**
  ATXN1            COL5A2         FAP              HISPPD2A         KIAA0467            MECP2              PPIA           RPL35A            TAGLN           **YWHAZ**
  AXL              COL6A1         FASN             HIST1H2AE        KIAA1881            MFAP4              PPIB           RPLP0             TALDO1          ZBTB4
  BASP1            COL6A2         FAT              HIST1H2BA        KPNB1               **MFGE8**          PPME1          RPS10             TAS2R60         ZNF134
  [BDNF]{.ul}      COL6A3         FAT2             HIST1H2BL        KRT1                MFSD2              PPP1CC         RPS16             TCN1            ZNF503
  BGN              COL7A1         FAT4             HIST1H4H         KRT10               [MIF]{.ul}         PRDM16         RPS18             TF              ZNF614
  BHMT2            COMP           FBLN1            HIST2H2BE        KRT13               [MMP1]{.ul}        PRDX1          RPS2              TFG             
  BRMS1            COPB1          FBN1             **HLAA**         KRT14               [MMP10]{.ul}       PRDX6          RPS24             TFRC            
  BSG              COPS3          FBN2             HMGCS2           KRT15               **[MMP2]{.ul}**    PRNP           RPS27A            TGFB1           
  ---------------- -------------- ---------------- ---------------- ------------------- ------------------ -------------- ----------------- --------------- ------------------

Regular font: identified by LC MS/MS.

[Underline:]{.ul} identified by antibody arrays.

**[Bold and Underline:]{.ul}** identified by both LC MS/MS and antibody arrays.

**Bold:** identified by LC MS/MS and was found to be present in at least 50% of exosomes characterized.
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